Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6075695 | 0.98 | HTR2C (0.61) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL9773283 | 0.88 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL27841195 | 0.88 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL27821867 | 0.88 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL31278837 | 0.86 | HTR2C (0.49) | HTR2C | |
| SCHEMBL29427088 | 0.84 | KDM1A (0.50) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30493303 | 0.84 | HTR2C (0.72) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL10046437 | 0.84 | KDM1A (0.50) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27604840 | 0.80 | KDM1A (0.47) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25604023 | 0.80 | KDM1A (0.47) | HTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3784655-B1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-112204007-B | Process for preparing 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2023-06-20 | — | — | CN | disclosed |
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| CN-109369632-B | Water-soluble aggregation-induced emission probe and preparation method and application thereof | 华中科技大学 | 2021-03-30 | — | — | CN | disclosed |
| EP-3784655-A1 | PROCESS FOR PREPARING 2-(1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-YL)BENZOIC ACID | Theravance Biopharma R&D IP, LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112204007-A | Process for the preparation of 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) benzoic acid | 施万生物制药研发IP有限责任公司 | 2021-01-08 | — | — | CN | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-05-05 | — | — | US | disclosed |
| CN-109369632-A | A kind of water solubility aggregation-induced emission probe and the preparation method and application thereof | 华中科技大学 | 2019-02-22 | — | — | CN | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
| US-10640467-B2 | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | BDNF, GABRE, NPY5R | HTR2C 568/4885SLC18A3 607/4885SIGMAR1 685/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885SLC18A3 162/4885SIGMAR1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.